ArticleNorthern clinics of Istanbul2025
Analysis of QuantiFERON
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveScreening for latent tuberculosis (LTB) is necessary, especially for people living with human immunodeficiency virus (HIV) and people receiving anti-TNF therapy. Although there is no microbiological test accepted as the gold standard, interferon-gamma release assays (IGRAs) are suggested to be used by World Health Organization. We aimed to analyze QuantiFERON
methodsPatients admitted to Marmara University Pendik Training and Research Hospital Microbiology Laboratory between August 2016 - March 2020 have been analyzed retrospectively. Patient demographic data was obtained from the records of the laboratory information management system. Blood samples have been studied as recommended by the manufacturer (QuantiFERON
resultsWe evaluated samples from 1506 patients, of whom with a chronic inflammatory disease (CID) in 1223 patients and HIV positivity among 283 patients. Mean age was 38.29±12.66 for HIV patients and 41.57±14.45 for chronic inflammatory disease patients. QFT test was positive in 319 (21.2%) of 1506 patients in total and in 43 (15.2%) of HIV patients and in 276 (22.6%) of CID patients. Indeterminate results were obtained in 1.7% (n=26) of the samples. Among patients with CID highest rate of QFT test positivity was detected among patients with psoriasis (27.8%), followed by patients with rheumatoid arthritis (21.8%) and ankylosing spondylitis (19.8%). Active tuberculosis was not developed in any of QFT-GIT-positive CID patients followed up in our hospital for the 4 years period.
conclusionQuantiFERON
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.